Haddad R - Search Results

1

Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.

Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R. Robinson BG, et al. Among authors: haddad r. J Clin Endocrinol Metab. 2010 Jun;95(6):2664-71. doi: 10.1210/jc.2009-2461. Epub 2010 Apr 6. J Clin Endocrinol Metab. 2010. PMID: 20371662 Free PMC article. Clinical Trial.

2

Vandetanib for the treatment of medullary thyroid cancer.

Chau NG, Haddad RI. Chau NG, et al. Clin Cancer Res. 2013 Feb 1;19(3):524-9. doi: 10.1158/1078-0432.CCR-12-2353. Epub 2012 Dec 11. Clin Cancer Res. 2013. PMID: 23231950 Review.

3

Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes.

Haddad RI, Schlumberger M, Wirth LJ, Sherman EJ, Shah MH, Robinson B, Dutcus CE, Teng A, Gianoukakis AG, Sherman SI. Haddad RI, et al. Endocrine. 2017 Apr;56(1):121-128. doi: 10.1007/s12020-017-1233-5. Epub 2017 Feb 3. Endocrine. 2017. PMID: 28155175 Free PMC article. Clinical Trial.

4

Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial.

Kreissl MC, Bastholt L, Elisei R, Haddad R, Hauch O, Jarząb B, Robinson B, Colzani R, Foster M, Weiss R, Schlumberger M. Kreissl MC, et al. Among authors: haddad r. J Clin Oncol. 2020 Aug 20;38(24):2773-2781. doi: 10.1200/JCO.19.02790. Epub 2020 Jun 25. J Clin Oncol. 2020. PMID: 32584630 Free PMC article.

5

A phase II study of gefitinib in patients with advanced thyroid cancer.

Pennell NA, Daniels GH, Haddad RI, Ross DS, Evans T, Wirth LJ, Fidias PH, Temel JS, Gurubhagavatula S, Heist RS, Clark JR, Lynch TJ. Pennell NA, et al. Among authors: haddad ri. Thyroid. 2008 Mar;18(3):317-23. doi: 10.1089/thy.2007.0120. Thyroid. 2008. PMID: 17985985 Clinical Trial.

6

New developments in thyroid cancer.

Haddad RI. Haddad RI. J Natl Compr Canc Netw. 2013 May;11(5 Suppl):705-7. doi: 10.6004/jnccn.2013.0207. J Natl Compr Canc Netw. 2013. PMID: 23704249 Review.

7

A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN).

Limaye S, Riley S, Zhao S, O'Neill A, Posner M, Adkins D, Jaffa Z, Clark J, Haddad R. Limaye S, et al. Among authors: haddad r. Oral Oncol. 2013 Aug;49(8):835-41. doi: 10.1016/j.oraloncology.2013.04.010. Epub 2013 May 30. Oral Oncol. 2013. PMID: 23727257 Clinical Trial.

8

Management of treatment-related toxicities in advanced medullary thyroid cancer.

Brose MS, Bible KC, Chow LQM, Gilbert J, Grande C, Worden F, Haddad R. Brose MS, et al. Among authors: haddad r. Cancer Treat Rev. 2018 May;66:64-73. doi: 10.1016/j.ctrv.2018.04.007. Epub 2018 Apr 22. Cancer Treat Rev. 2018. PMID: 29704768 Review.

9

A phase I/II trial of sapanisertib in advanced anaplastic and radioiodine refractory differentiated thyroid carcinoma.

Sehgal K, Serritella A, Liu M, ONeill A, Nangia C, Pappa T, Demeure MJ, Worden FP, Haddad R, Lorch J. Sehgal K, et al. Among authors: haddad r. J Clin Endocrinol Metab. 2024 Jun 29:dgae443. doi: 10.1210/clinem/dgae443. Online ahead of print. J Clin Endocrinol Metab. 2024. PMID: 38943664

10

Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study.

Haddad R, Colevas AD, Krane JF, Cooper D, Glisson B, Amrein PC, Weeks L, Costello R, Posner M. Haddad R, et al. Oral Oncol. 2003 Oct;39(7):724-7. doi: 10.1016/s1368-8375(03)00097-6. Oral Oncol. 2003. PMID: 12907212 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,241 results

Search Page

Filters